Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Sheba Medical Center90 enrolled

Overview

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Leukemia, Myeloid, Philadelphia-Positive

Interventions

Pegylated Interferon and ImatinibDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of imatinib therapy. Exclusion Criteria: * Patients in imatinib study * Patients with a history of intolerability to interferon. * Patients with less than CCR or less than one year of imatinib therapy.

Locations (1)

Department of Hematology, Sheba Medical Center

Tel Litwinsky, Tel-Hashomer, Israel

RECRUITING

Central Contacts

Izhar Hardan, MD

CONTACT

+972 3 5302174 izhar.hardan@sheba.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.